1-8 of 8
Jourik A. Gietema
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Marjolijn N. Lub-de Hooge, Iris C. Kok, Adrienne H. Brouwers, Sjoerd G. Elias, Margaret T.L. Nguyen, Hong Lu, Jourik A. Gietema, Mathilde Jalving, Derk J.A. de Groot, Olga Vasiljeva, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5325–5333.
https://doi.org/10.1158/1078-0432.CCR-21-0453
Published: 01 October 2021
View article titled, First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
Open the PDF for First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup>Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody in another window
Includes: Supplementary data
Journal Articles

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok, Frans V. Suurs, Adrienne H. Brouwers, C. Willemien Menke-van der Houven van Oordt, Thijs T. Wind, Jourik A. Gietema, Carolien P. Schröder, Shekar V.K. Mahesh, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3517–3527.
https://doi.org/10.1158/1078-0432.CCR-18-2918
Published: 14 June 2019
View article titled, <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Open the PDF for <sup>89</sup>Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake in another window
Includes: Supplementary data
Journal Articles

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Frederike Bensch, Laetitia E. Lamberts, Michaël M. Smeenk, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Marlene Thomas, Wolfgang Jacob, Keelara Abiraj, Celine Adessi, Georgina Meneses-Lorente, Ian James, Martin Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6128–6137.
https://doi.org/10.1158/1078-0432.CCR-17-0311
Published: 12 October 2017
View article titled, <sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
Open the PDF for <sup>89</sup>Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, Eva J. ter Weele, Frederike Bensch, Michiel M. Smeenk, Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub-de Hooge, Henk M.W. Verheul, Sandra M. Sanabria Bohorquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1642–1652.
https://doi.org/10.1158/1078-0432.CCR-15-1272
Published: 31 March 2016
View article titled, ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment
Open the PDF for ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment in another window
Includes: Supplementary data
Journal Articles

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis, Jourik A. Gietema, Norma Lynn Fox, Renée Miceli, Ferry A.L.M. Eskens, Walter J. Loos, Elisabeth G.E. de Vries, Stefan Sleijfer
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5584–5590.
https://doi.org/10.1158/1078-0432.CCR-09-0996
Published: 31 August 2009
View article titled, Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study
Open the PDF for Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications

Elisabeth G.E. de Vries, Jourik A. Gietema, Steven de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (8): 2390–2393.
https://doi.org/10.1158/1078-0432.CCR-06-0352
Published: 25 April 2006
View article titled, Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications
Open the PDF for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications in another window
Journal Articles

Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

Linda E. Bröker, Filip Y.F.L. de Vos, Cees J. van Groeningen, Bart C. Kuenen, Helen E. Gall, Michael H. Woo, Maurizio Voi, Jourik A. Gietema, Elisabeth G.E. de Vries, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1760–1767.
https://doi.org/10.1158/1078-0432.CCR-05-2093
Published: 21 March 2006
View article titled, Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity
Open the PDF for Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity in another window
Journal Articles

Correspondence re: C. G. Ferreira et al. , Apoptosis: Target of Cancer Therapy. Clin. Cancer Res., 8: 2024–2034, 2002.

Elisabeth G. E. de Vries, Marjolein N. de Hooge, Jourik A. Gietema, Steven de Jong
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 912.
Published: 01 February 2003
View article titled, Correspondence re: C. G. Ferreira <em>et al.</em> , Apoptosis: Target of Cancer Therapy. Clin. Cancer Res., <em>8:</em> 2024–2034, 2002.
Open the PDF for Correspondence re: C. G. Ferreira <em>et al.</em> , Apoptosis: Target of Cancer Therapy. Clin. Cancer Res., <em>8:</em> 2024–2034, 2002. in another window